The 20 Best Late-Onset Retinal Degeneration Doctors Near Me

Peter Kaiser is an Ophthalmologist practicing medicine in Cleveland, Ohio. He has been practicing medicine for over 38 years. Dr. Kaiser is rated as an Elite provider by MediFind in the treatment of Late-Onset Retinal Degeneration. He is also highly rated in 26 other conditions, according to our data. His clinical expertise encompasses Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Diabetic Retinopathy, Vitrectomy, and Osteotomy. Dr. Kaiser is board certified in American Board Of Ophthalmology, 1998.

I’m a retina specialist who takes care of patients who have problems with the back of the eye. When a patient comes to see me, I like getting to know them and their history, so that I can tailor their treatment. My patients come from a variety of different backgrounds, so I find that I often learn as much from them as they do from me. Everybody has a different story and I very much like to learn about the patients to whom I provide care. Duke is a great place at which to work and from which to seek treatment because it’s a very collaborative institution. Everyone works together to do what’s best for the patient. Outside of work, I like to spend as much time as possible with my family. I also enjoy cooking, playing sports and watching sports. Dr. Jaffe is rated as an Elite provider by MediFind in the treatment of Late-Onset Retinal Degeneration. He is also highly rated in 22 other conditions, according to our data. His clinical expertise encompasses Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Geographic Atrophy, Vitrectomy, and Cataract Removal. Dr. Jaffe is board certified in American Board Of Ophthalmology, Ophthalmology.

Peter A. Campochiaro, M.D. is the George S. and Dolores Doré Eccles Professor of Ophthalmology and Neuroscience at the Wilmer Eye Institute, Johns Hopkins University School of Medicine. He is a clinician-scientist who directs a research laboratory and conducts clinical trials. His laboratory research is directed at understanding the pathogenesis of ocular neovascularization and excessive retinal vascular permeability, and the mechanism of cone cell death in inherited retinal degenerations. He helped to determine the importance of vascular endothelial growth factor (VEGF), hypoxia-inducible factor-1, and Tie2 in retinal and choroidal vascular diseases. The clinical trial group under Dr. Campochairo provided the first demonstration of the benefits of suppression of VEGF in diabetic macular edema and retinal vein occlusion. He has developed strategies for sustained suppression of VEGF that are currently being tested in clinical trials. Dr. Campochiaro trained at the University of Notre Dame, Johns Hopkins School of Medicine, and the University of Virginia. He did a vitreoretinal fellowship and research fellowships at Johns Hopkins and joined the faculty of the University of Virginia in 1984. He became professor of Ophthalmology and Neuroscience at the Wilmer Eye Institute, Johns Hopkins in 1991. Dr. Campochiaro is rated as an Elite provider by MediFind in the treatment of Late-Onset Retinal Degeneration. He is also highly rated in 18 other conditions, according to our data. His clinical expertise encompasses Retinal Vein Occlusion, Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), Trabeculectomy, and Vitrectomy. Dr. Campochiaro is board certified in American Board Of Ophthalmology.

Dr. Neil Bressler has been a member of the Wilmer Eye Institute's faculty since 1988 and is the inaugural James P. Gills Professor of Ophthalmology. He specializes in retinal diseases, with special interests in diabetic retinopathy and macular degeneration. Dr. Bressler's main research interests have been collaborative efforts in clinical trials of common retinal diseases, including age-related macular degeneration and diabetic retinopathy, having chaired several NIH-sponsored and industry-sponsored multicenter randomized clinical trials and authored almost 300 peer-reviewed publications. He is a past chair of the NIH-sponsored Diabetic Retinopathy Clinical Research Network, and was responsible for guidelines, policies, protocol development as well as implementation, and to facilitate Network operations in a way that maintains academic integrity and optimal clinical trial performance. He also has chaired the National Eye Institutes Data and Safety Monitoring Committee for intramural clinical trials and the FDA Ophthalmic Devices Panel. Dr. Bressler is currently editor-in-chief of JAMA Ophthalmology. Dr. Bressler is rated as an Elite provider by MediFind in the treatment of Late-Onset Retinal Degeneration. He is also highly rated in 17 other conditions, according to our data. His clinical expertise encompasses Diabetic Macular Edema (DME), Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Vitrectomy, and Cataract Removal. Dr. Bressler is board certified in American Board Of Ophthalmology.

Jennifer Sun is an Ophthalmologist practicing medicine in Boston, Massachusetts. Dr. Sun is rated as an Elite provider by MediFind in the treatment of Late-Onset Retinal Degeneration. She is also highly rated in 6 other conditions, according to our data. Her clinical expertise encompasses Diabetic Retinopathy, Diabetic Macular Edema (DME), Age-Related Macular Degeneration (ARMD), Vitrectomy, and Cataract Removal. Dr. Sun is board certified in American Board Of Ophthalmology.

David Eichenbaum is an Ophthalmologist practicing medicine in St Petersburg, Florida. Dr. Eichenbaum is rated as an Elite provider by MediFind in the treatment of Late-Onset Retinal Degeneration. He is also highly rated in 12 other conditions, according to our data. His clinical expertise encompasses Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Geographic Atrophy, Diabetic Macular Edema (DME), and Vitrectomy. Dr. Eichenbaum is board certified in American Board Of Ophthalmology.

Veeral Sheth is an Ophthalmologist practicing medicine in Oak Forest, Illinois. Dr. Sheth is rated as an Elite provider by MediFind in the treatment of Late-Onset Retinal Degeneration. He is also highly rated in 11 other conditions, according to our data. His clinical expertise encompasses Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Diabetic Macular Edema (DME), Diabetic Retinopathy, and Vitrectomy. Dr. Sheth is board certified in American Board Of Ophthalmology.

Dr. Abbey graduated magna cum laude from Harvard University and received his medical degree, with honors, at Weill Cornell Medical College in New York, NY. He completed his transitional residency at Scripps Mercy Hospital in San Diego, CA, and his ophthalmology residency at Bascom Palmer Eye Institute in Miami, FL. He then completed his fellowship in vitreoretinal surgery at William Beaumont Hospital in Royal Oak, MI. Dr. Abbey specializes in the management of all diseases of the retina and vitreous. His clinical expertise includes the diagnosis and treatment of macular degeneration, retinal detachment, diabetic retinopathy, macular holes, retinopathy of prematurity and other pediatric retinal diseases. He has been active in research during his medical career and has published numerous peer-reviewed scientific papers, book chapters and national meeting abstracts on various ophthalmologic topics. Dr. Abbey is board-certified in ophthalmology. He is an active fellow of the American Academy of Ophthalmology and is an active member of the American Society of Retina Specialists, the Association for Research in Vision and Ophthalmology and the Alpha Omega Alpha Honor Medical Society. He also serves as a manuscript referee for the standard scientific journal of his field, RETINA: The Journal of Retina and Vitreous Diseases. Dr. Abbey is rated as an Elite provider by MediFind in the treatment of Late-Onset Retinal Degeneration. He is also highly rated in 38 other conditions, according to our data. His clinical expertise encompasses Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Geographic Atrophy, Vitrectomy, and Cataract Removal. Dr. Abbey is board certified in Ophthalmology- American Board Of Ophthalmology.

Ehsan Rahimy is an Ophthalmologist practicing medicine in San Carlos, California. He has been practicing medicine for over 17 years. Dr. Rahimy is rated as an Elite provider by MediFind in the treatment of Late-Onset Retinal Degeneration. He is also highly rated in 18 other conditions, according to our data. His clinical expertise encompasses Retinal Vein Occlusion, Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Vitrectomy, and Cataract Removal. Dr. Rahimy is board certified in Ophthalmology - Board Certified. Dr. Rahimy is currently accepting new patients.

Jay Chhablani is an Ophthalmologist practicing medicine in Pittsburgh, Pennsylvania. Dr. Chhablani is rated as an Elite provider by MediFind in the treatment of Late-Onset Retinal Degeneration. He is also highly rated in 27 other conditions, according to our data. His clinical expertise encompasses Central Serous Chorioretinopathy, Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), Vitrectomy, and Cataract Removal. Dr. Chhablani is currently accepting new patients.

Yannis M. Paulus, M.D., F.A.C.S., is the Jonas Fridenwald Professor in Ophthalmology, an associate professor in the Johns Hopkins University Department of Ophthalmology and Department of Biomedical Engineering, and a vitreoretinal surgeon at the Wilmer Eye Institute, Johns Hopkins Medicine’s East Baltimore and Columbia locations. Dr. Paulus served as a surgical retina specialist and director of a research laboratory at the University of Michigan Kellogg Eye Center for almost 10 years, where he developed novel imaging systems, lasers and long-lasting therapies and nanotechnologies to allow physicians to determine cellular markers of disease, enabling early diagnosis, improved treatment monitoring and more individualized, personalized precision medicine tailored to each patient’s needs. After earning his bachelor’s degree in chemistry and physics from Harvard University and his medical degree at Stanford University School of Medicine, Dr. Paulus completed an internship at the Sloan-Kettering Cancer Center, a residency in ophthalmology at the Stanford University School of Medicine Byers Eye Institute, and a surgical and medical retina fellowship at Wilmer Eye Institute, Johns Hopkins Medicine. CVhttps://www.hopkinsmedicine.org/-/media/wilmer/documents/cvs/Paulus_CV%2021225.pdf. Dr. Paulus is rated as an Elite provider by MediFind in the treatment of Late-Onset Retinal Degeneration. He is also highly rated in 17 other conditions, according to our data. His clinical expertise encompasses Diabetic Retinopathy, Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), Vitrectomy, and Cataract Removal. Dr. Paulus is board certified in American Board Of Ophthalmology.

Sunir Garg is an Ophthalmologist practicing medicine in Philadelphia, Pennsylvania. Dr. Garg is rated as an Elite provider by MediFind in the treatment of Late-Onset Retinal Degeneration. He is also highly rated in 20 other conditions, according to our data. His clinical expertise encompasses Endophthalmitis, Retinal Detachment, Age-Related Macular Degeneration (ARMD), Vitrectomy, and Cataract Removal. Dr. Garg is board certified in Ophthalmology. Dr. Garg is currently accepting new patients.

Dr. Dante J. Pieramici graduated with honors from the Johns Hopkins University School of Medicine and completed Ophthalmology Residency at the Wilmer Eye Institute. He receive vitreoretinal fellowship training at the Emory Eye Center in Atlanta Georgia. Dr. Pieramici has held full-time academic positions at the Yale University Eye Center and the Wilmer Eye Institute, where he served as the Assistant Chief of Service and Director of Ocular Trauma. Currently he is the Codirector of the California Retina Research Foundation, a partner of the California Retina Consultants, and Assistant Clinical Professor of Ophthalmology at the Doheny Eye Center in Southern California. Dr. Pieramici has published over 100 articles, 16 book chapters, and has edited 3 books on retinal diseases. He lectures nationally and internationally on retinal diseases and ocular trauma.Dr. Pieramici’s research interests have been varied, and include clinical and basic science projects aimed at better understanding of the underlying pathophysiology of ocular diseases, so as to improve treatments for patients with age-related macular degeneration, diabetic retinopathy, retinal vascular diseases, and severe ocular injuries. He has been a clinical investigator, principal investigator, or reading center investigator in numerous NIH and pharmaceutical company sponsored clinical trials. Dr Pieramici has helped in the development of new surgical techniques including limited macular translocation and 25-gauge (small incision) vitrectomy surgery. Currently he is involved in the development of new drug delivery techniques for various retinal vascular diseases.Dr. Pieramici has received the Achievement Award from the American Academy of Ophthalmology and Honor Award from the American Society of Retinal Specialists. He is a member of the American Academy of Ophthalmology, the Retina Society, the Macula Society, the American Society of Retinal Specialists, the Association for Research in Vision and Ophthalmology, the American Society of Ocular Trauma where he serves as Vice President, and the Pan-American Ophthalmologic Society amongst others. Dr Pieramici is a member of S.E.E International and regularly trains international ophthalmologists from undeserved areas.As vitreoretinal specialists, we provide comprehensive medical and surgical treatment for all disorders of the retina, macula and vitreous. We focus on the diagnosis, prevention and treatment of these conditions. Many abnormalities of the retina and vitreous may cause visual loss. These disorders include macular degeneration, diabetic retinopathy, retinal detachment, macular holes, macular edema and epiretinal membranes. Our practice has multiple locations throughout Central California to serve our patients. Dr. Pieramici is rated as an Elite provider by MediFind in the treatment of Late-Onset Retinal Degeneration. He is also highly rated in 19 other conditions, according to our data. His clinical expertise encompasses Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Diabetic Macular Edema (DME), Diabetic Retinopathy, and Vitrectomy. Dr. Pieramici is board certified in Ophthalmology. Dr. Pieramici is currently accepting new patients.

James T. Handa, M.D., is Chief of the Retina Division and the Robert Bond Welch, M.D., Professor of Ophthalmology at the Wilmer Eye Institute. He specializes in medical and surgical management of complex vitreoretinal diseases such as age-related macular degeneration, diabetic retinopathy, retinal detachment, retinopathy of prematurity and other pediatric retinal diseases. He also has expertise in intraocular oncology and manages patients with choroidal melanomas and metastatic tumors of the eye. Not only is he a highly skilled surgeon and clinician, but he also devotes significant effort to research related to the early causes of age-related macular degeneration using molecular pathological approaches to understand how the eye transforms from normal aging to early disease. He has been funded by the National Eye Institute for the last 19 years, and he currently holds two R01 awards for his work in AMD. He has also been funded by the Thome Foundation, Research to Prevent Blindness, Fight for Sight and the American Health Assistance Foundation. His other research focuses on surgical innovation using an integrated robotic surgical system. Dr. Handa is currently the Wilmer Eye Institute’s implanting surgeon for the Argus II retinal chip implant, which was recently approved by the FDA after Dr. Handa participated in the clinical trial leading to its approval. Dr. Handa is rated as an Elite provider by MediFind in the treatment of Late-Onset Retinal Degeneration. He is also highly rated in 12 other conditions, according to our data. His clinical expertise encompasses Melanoma of the Eye, Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), Metastatic Uveal Melanoma, and Vitrectomy. Dr. Handa is board certified in American Board Of Ophthalmology.

Dr. Small is a board-certified ophthalmologist with years of specialized training and over two decades of experience in retinal disorders, making him a leading expert in his field. Using the very latest methods, Dr. Small can diagnose and treat the full spectrum of retinal disorders, including diabetic retinopathy, macular degeneration, retinal detachments, retinal vascular disease and more. Throughout his career, Dr. Small has been involved in research and clinical trials backed by over $10 million in funding that will improve patient care for years to come. Dr. Small is also the published author of over 300 articles relating to all aspects of retinal disease. For over a decade, Dr. Small was both Professor and Director of the Macular Disease Center and Retinal Research lab at the Jules Stein Eye Institute at UCLA. He has taught nearly 100 ophthalmologists and optometrists. In addition, Dr. Small is a frequent guest lecturer and recognized expert both nationally and internationally.Finally, Dr. Small will treat you with the utmost concern and compassion you deserve every step of the way. Your appointments with him are unhurried and informative, and he will explain everything to you in simple, easy-to-understand language. It's why Dr. Kent Small is trusted by nearly 300 Glendale and Los Angeles area ophthalmologists, optometrists and other medical specialists for their patients who need retinal care.Innovative, experienced and highly personalized retinal care. Dr. Small is rated as an Elite provider by MediFind in the treatment of Late-Onset Retinal Degeneration. He is also highly rated in 11 other conditions, according to our data. His clinical expertise encompasses Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Endophthalmitis, Retinal Vein Occlusion, and Vitrectomy. Dr. Small is board certified in Ophthalmology. Dr. Small is currently accepting new patients.

Andrew Schachat is an Ophthalmologist practicing medicine in Cleveland, Ohio. He has been practicing medicine for over 51 years. Dr. Schachat is rated as an Elite provider by MediFind in the treatment of Late-Onset Retinal Degeneration. He is also highly rated in 19 other conditions, according to our data. His clinical expertise encompasses Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Diabetic Retinopathy, Vitrectomy, and Cataract Removal. Dr. Schachat is board certified in American Board Of Ophthalmology, 1983.

As a medical retina specialist, I am passionate about providing state-of-the-art care to patients with age-related macular degeneration, diabetic retinopathy, retinal vein occlusion, and other macular diseases. I approach each patient as an individual and strive to provide care that addresses his or her unique needs and goals. For each of my patients, I carefully consider exam findings and results of advanced retinal imaging studies and use this information to design a personalized treatment strategy. In my role as a physician, I enjoy most the enduring relationships that I build with patients and their families, and the opportunities that I have to make a lasting positive impact on their lives. In addition to patient care, I maintain an active clinical and laboratory research program. I am actively involved in clinical trials of new treatments for age-related macular degeneration and diabetic retinopathy, and in studies of new imaging technologies for improved diagnosis and monitoring of macular diseases. Outside of work, I enjoy spending time with my wife and children. Dr. Mettu is rated as an Elite provider by MediFind in the treatment of Late-Onset Retinal Degeneration. He is also highly rated in 7 other conditions, according to our data. His clinical expertise encompasses Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Geographic Atrophy, and Diabetic Retinopathy. Dr. Mettu is board certified in American Board Of Ophthalmology, Ophthalmology.

Mandeep S. Singh, M.D., Ph.D., is associate professor of ophthalmology and genetic medicine in the Retina Division of the Wilmer Eye Institute and the recipient of the 2023 Andreas C. Dracopoulos Professorship in Ophthalmology. Dr. Singh is a retinal specialist. He is Co-Director of the Genetic Eye Disease (GEDi) Center, and is a principal investigator at the Center for Stem Cells and Ocular Regenerative Medicine (STORM). Dr. Singh completed his medical degree at the National University of Singapore. In 2009, he was elected to the Fellow of the Royal College of Surgeons of Edinburgh. He earned a PhD in ophthalmology from the University of Oxford, United Kingdom, in 2014. He completed fellowships in vitreoretinal diseases and surgery at the Oxford Eye Hospital and Moorfields Eye Hospital, both in the United Kingdom. His clinical expertise includes surgical, medical and genetic conditions of the retina and macula. Dr. Singh is specialty-trained in vitrectomy surgery for retinal detachment, macular holes, macular pucker, epiretinal membrane, proliferative vitreoretinopathy, complex retinal detachments including reoperations, vitreous hemorrhage removal, and other retinal surgeries. He also specializes in age-related macular degeneration, diabetic retinopathy, diabetic macular edema, retinal vein occlusion, and choroidal neovascularization. Dr. Singh sees patients and families with genetic retinal diseases such as retinitis pigmentosa, Usher syndrome, Stargardt disease and macular dystrophies. His research focus is retinal stem cell transplantation. Dr. Singh’s work has been recognized through the Eye Institute–Allergan Research Prize, the Merton College University of Oxford Graduate Prize Scholarship, the Oxford Ophthalmological Congress Founder’s Cup and Medal, the Ruskell Medal, the Johns Hopkins Clinician Scientist Award, and the Bert M. Glaser, MD Award for Innovative Research in Retina. He is a member of the American Academy of Ophthalmology and the Association for Research in Vision and Ophthalmology. He is also a member of the Club Jules Gonin and the Macula Society. CV https://www.hopkinsmedicine.org/-/media/wilmer/documents/cvs/Singh_CV.pdf. Dr. Singh is rated as an Elite provider by MediFind in the treatment of Late-Onset Retinal Degeneration. He is also highly rated in 19 other conditions, according to our data. His clinical expertise encompasses Retinitis Pigmentosa, Stargardt Macular Degeneration, Late-Onset Retinal Degeneration, Retinopathy Pigmentary Mental Retardation, and Vitrectomy.

Mathew Maccumber is an Ophthalmologist practicing medicine in Chicago, Illinois. Dr. Maccumber is rated as an Elite provider by MediFind in the treatment of Late-Onset Retinal Degeneration. He is also highly rated in 38 other conditions, according to our data. His clinical expertise encompasses Retinal Detachment, Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Geographic Atrophy, and Vitrectomy. Dr. Maccumber is board certified in American Board Of Ophthalmology.

I am a Duke vitreoretinal surgeon and Moorfields uveitis trained ophthalmologist, specializing in patients with complex medical and surgical problems of the back of the eye, known as the retina, as well as patients with inflammation in the eye or uveitis. I use the latest diagnostic and therapeutic methods along with a collaborative team effort with colleagues across Duke Eye Center and the Duke Rheumatology and Immunology division to develop the optimum treatment plans for patients with uveitis. Outside of work, I enjoy spending time with the family, traveling, watching sports, and landscape photography. Dr. Grewal is rated as an Elite provider by MediFind in the treatment of Late-Onset Retinal Degeneration. He is also highly rated in 32 other conditions, according to our data. His clinical expertise encompasses Uveitis, Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Vitrectomy, and Cataract Removal. Dr. Grewal is board certified in American Board Of Ophthalmology, Ophthalmology.